Oxford Cannabinoid Techn... Share Discussion Threads

[burtond1] 27/12/2023 07:25

10 Companies to follow in 2024https://total-market-solutions.com/2023/12/10-companies-to-follow-in-2024/

[sep800] 11/12/2023 11:44

Anyone have any idea when phase 2 will commence ? We can do with an update especially as the markets awaits any funding update due in Q1 or Q2 2024.

[burtond1] 24/10/2023 06:15

A plants beauty lies in its leaves, but its strength lies in its roots."...I am excited to be buying more #OCTP personally. Given the recent Phase I results, the Company appears to me to be significantly undervalued. It is for this reason that I, along with other shareholders and employees of Kingsley, have chosen to increase our direct holding in the business..."https://total-market-solutions.com/2023/10/oxford-cannabinoid-technologies-plc-3/

[burtond1] 20/10/2023 07:39

Good news this for #OCTP and a massive vote of confidence...Kingsley Capital Partners LLP has sold 39,464,286 shares in the Company to Shareholders of Kingsley and has transferred 15,400,000 shares in the Company to employees of Kingsley. Important this. It enables a number of investors who have long been part of the OCT story to be able to express their support for the business as individual shareholders. It clearly is a sign of growing confidence in OCT that investors want personally to become a part of the journey following last week's Phase I announcement. Kingsley continues to be the largest shareholder in OCT. Neil Mahapatra, Non-Executive Director of OCT and Managing Partner of Kingsley Capital Partners LLP, said: "I am excited to be buying more into OCT personally. Given the recent Phase I results, the Company appears to me to be significantly undervalued. It is for this reason that I, along with other shareholders and employees of Kingsley, have chosen to increase our direct holding in the business."

[sep800] 10/10/2023 09:59

Nice to received a positive RNS this morning as expected. Phase 2 onwards and upwards.
Markets will soon wake up to OCTP

[paulhopeful] 10/10/2023 09:02

CEO said, “Very pleased to report absolutely fine, no adverse events, all looking good from a safety and tolerability point of view” Excellent news, all positive, should move quickly to phase 2.

[jasko] 10/10/2023 08:23

2p will come but only with funding in place IMHO

[jambam] 10/10/2023 07:04

2P COMING!!!

[bibdaddy] 10/10/2023 06:57

Missed the boat?

[thiopia] 10/10/2023 06:43

cripes, this eats cash

Financial Highlights

· Robust balance sheet, debt-free with cash reserves of approximately £2.3m at year-end (30 April 2022: £9.2m). Cash is forecast to be fully utilised by April 2024.

· Cash absorbed by operations of £7.0m (FY2022: £5.4m); Loss for year of £5.9m (30 April 2022: £4.7m).

[paulhopeful] 03/10/2023 15:02

Often the way, should explode when the good news arrives soon, chances of success are extremely high.

[bibdaddy] 03/10/2023 14:33

Anybody know the reason for the drop with news not too far away?

[sep800] 29/9/2023 14:06

Very quite on here lately. Not long for confirmation of phase 1 complete. I think we have been hinted that no adverse effect therefore expecting phase 2 fairly soon. Been a long road since IPO and the share price needs some recovery. However at this level take advantage of the very low current share price Funded till next April 2024 and expect a JV or share offer to existing shareholders at a much higher level than currently. Plenty other products in the pipeline and I would expect OCTP would be a great performer during 2024.
GLA

[bibdaddy] 25/9/2023 06:03

Promising trial update this morning

[paulhopeful] 21/9/2023 13:13

Will we receive results just before the AGM, I’m looking forward to them, and phase two.

[sep800] 20/9/2023 14:29

phase 1 results must be near,
expecting positive news with phase 2 underway... crazy M/C considering all the products in the pipeline.

[burtond1] 14/9/2023 06:21

Capital Re-Organisation Questions..Does this help. This is the way i see it... It's a purely a procedural process allowing the Company to reduce the nominal value of its shares from 1p to 0.1p WITHOUT diluting existing shareholders as the Companies Act prohibits companies from issuing shares at below the nominal value. It'll have ZERO impact on shareholders - no new ordinary shares are being issued. The reason for it is to allow the company to take advantage of the general authority to issue new shares (up to 20% of share capital only) it's requesting at the AGM - that means the Company is able to be more agile as and when it wants to raise some cash. This is all subject to a shareholder vote at the AGM so is entirely in shareholder control. There's no impact on existing warrants currently issued by the company, which have a 5p/share exercise price. There's nothing fishy going on! Amy more thoughts or questions please send to me and i can try and pass on to the BOD if thats helps? david [e-mail]

[jambam] 13/9/2023 09:16

Phase 1 update coming up :)

[paulhopeful] 02/9/2023 14:57

Have read all there is to know about this company, I think all that’s needed is patience. It’s good to read.

[paulhopeful] 01/9/2023 19:24

When you see what they have, I think anyone can see, there chances of success are extremely good, and worth while.

[paulhopeful] 01/9/2023 19:20

Though their outsourced model, OCTP Have created a portfolio of drugs, with over 20 billion available market. Targeting a serviceable market of 1.55 billion, with its first two drugs.